ZEVASKYN Revenue Hits $11.4 Million in Q2 Ahead of Abeona’s Q3 Update
Key Facts
ZEVASKYN generated net revenue of $11.4 million in the second quarter of 2026, compared with $8.7 million in the first quarter, a sequential increase of 31%, according to Abeona Therapeutics’ second-quarter results statement. These figures represent the company’s latest confirmed quarterly revenue in the available information and provide context for assessing the product’s commercial trajectory. The company said five patients received treatment during the quarter, but recorded revenue for only four treatments. It attributed the difference to one batch that did not meet the required platelet threshold for revenue recognition. The chief executive said the company expects growing real-world experience at active centers to contribute to broader adoption and long-term growth.
Alongside sales growth, Abeona recorded a net loss of $20.2 million, or $0.35 per share, in the second quarter ended June 30, 2026. The loss was $17.1 million, or $0.30 per share, in the first quarter, meaning it widened between the two periods. Cash, cash equivalents and short-term investments totaled $146.8 million on June 30, compared with $191.4 million on December 31, 2025. The company said its network of qualified ZEVASKYN treatment centers included seven U.S. sites in its second-quarter update. The network expansion comes as the company seeks to support use of the treatment and develop its commercial business.
The U.S. Food and Drug Administration approved ZEVASKYN on April 28, 2025, to treat wounds in adults and children with recessive dystrophic epidermolysis bullosa. The agency describes the product as an autologous cell-sheet-based gene therapy for wounds in people with the disease. The approval was based on the Phase 3 VIITAL study, a randomized, open-label study that compared treated wounds with control wounds in the same patient over 24 weeks. The study showed greater improvement in wound healing and pain reduction in treated wounds than in control wounds. This regulatory basis enables the company to market the treatment to the populations covered by the agency’s approval.
Abeona said the treatment’s NTAP status took effect on October 1, 2026, as part of fiscal 2027. The status gives eligible hospitals a route to request a supplemental payment from the Centers for Medicare and Medicaid Services on top of the base DRG payment when treating Medicare beneficiaries. The company said Medicare beneficiaries account for about 10% of patients with recessive dystrophic epidermolysis bullosa, and that NTAP status is expected to support hospital adoption and facilitate access to treatment. The arrangement’s impact is focused on the reimbursement pathway for eligible hospitals when they provide treatment to covered beneficiaries. NTAP status itself took effect on the date specified by the company.
In the stock market, Abeona Therapeutics shares closed at $4.17 in the November 6, 2026, session. The close came before the news date, November 9, while the available confirmed information does not include a third-quarter revenue figure that can be attributed to that date. The confirmed quarterly comparison in this data therefore remains the increase in ZEVASKYN revenue from $8.7 million in the first quarter to $11.4 million in the second quarter. The liquidity figures cited also remain tied to June 30, not the end of the third quarter. NTAP status took effect on October 1, the later-dated development in the available information about the treatment.